Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial

Headache

Volumn 51, Issue 1, 2011, Pages 73-84

  Connor, Kathryn M ^a   Aurora, Sheena K ^b   Loeys, Tom ^c   Ashina, Messoud ^d   Jones, Christopher ^a   Giezek, Hilde ^c   Massaad, Rachid ^c   Williams Diaz, Angela ^a   Lines, Christopher ^a   Ho, Tony W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Swedish Headache Center   (United States)

^c Merck Sharp and Dohme   (Belgium)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

CGRP; migraine; rizatriptan; safety; telcagepant

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; PLACEBO; RIZATRIPTAN; TELCAGEPANT;

ACUTE DRUG ADMINISTRATION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; BIPOLAR DISORDER; CONFUSION; DIARRHEA; DISEASE SEVERITY; DISSOCIATIVE DISORDER; DOUBLE BLIND PROCEDURE; DRUG ABUSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSESTHESIA; ELECTROCARDIOGRAPHY; EUPHORIA; FATIGUE; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NAUSEA; ORAL PARESTHESIA; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK ASSESSMENT; SIDE EFFECT; SOMNOLENCE; SYNCOPE; THORAX PAIN; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN; VOMITING; XEROSTOMIA;

ADULT; AGED; AZEPINES; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; MIGRAINE DISORDERS; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; TRIAZOLES; TRYPTAMINES;

EID: 78650925201     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2010.01799.x     Document Type: Article

References (15)

1. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ,. Oral triptans (serotonin 5-HT-1B/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet. 2001; 358: 1668-1675.
2. Doods H, Arndt K, Rudolf K, Just S,. CGRP antagonists: Unravelling the role of CGRP in migraine. Trends Pharmacol Sci. 2007; 28: 580-587.
3. Edvinsson L,. Novel migraine therapy with calcitonin gene-regulated peptide receptor antagonists. Expert Opin Ther Targets. 2007; 11: 1179-1188.
4. Goadsby PJ,. Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches. Drugs. 2005; 65: 2557-2567.
5. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004; 350: 1104-1110.
6. Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008; 70: 1304-1312.
7. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008; 372: 2115-2123.
8. Connor KM, Shapiro RE, Diener H-C, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009; 73: 970-977.
9. Ho AP, Dahlof CGH, Silberstein SD, et al. Randomized, controlled, trial of telcagepant over four migraine attacks. Cephalalgia. 2010; In press.
10. Whyte CA, Tepper SJ,. Adverse effects of medications commonly used in the treatment of migraine. Expert Rev Neurother. 2009; 9: 1379-1391.
11. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004; 24 (Suppl. 1): 9-160.
12. Lipton RB, Stewart WF, Sawyer J, Edmeads JG,. Clinical utility of an instrument assessing migraine disability: The Migraine Disability Assessment (MIDAS) questionnaire. Headache. 2001; 41: 854-861.
13. Blanchard R, Sun H, McCrea J, et al. A clinical study demonstrates no potential for recreational abuse of telcagepant. Headache. 2010; 50: 54.Abstract PO-115.
14. Dodick D, Lipton RB, Martin V, et al. Consensus statement: Cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache. 2004; 44: 414-425.
15. Merck Sharp & Dohme Corp. Merck Announces First-Quarter 2009 Financial Results [Company Press Release, April 21, 2009]. Merck Web site. Accessed October 25, 2010.